Tag: research

Deputax-M failed to meet its target overall survival during an interim analysis of a phase 3 clinical trial in glioblastoma

Nivolumab, an immunotherapy drug, has been unsuccessful in improving overall survival in a phase 3 clinical trial when tested in newly diagnosed glioblastoma with unmethylated MGMT

New research from one of our funded grants gives much needed insight into group 3 and 4 medulloblastoma

A research team from Germany has used artificial intelligence to improve the assessment of treatment response in brain tumours

NHS England are currently running a questionnaire to find out more about people’s experiences of Personal Health Budgets, which could feed into and shape the future of personalised healthcare

We’re thrilled to be the first ever UK charity to partner with the US-based Center for Advancing Innovation (CAI), an organisation dubbed ‘Tinder for start-ups’. We’ll be co-funding a pioneering initiative coordinated by the CAI, called The Brain Race. This will ask researchers and inventors from across the world to submit innovative ideas aimed at defeating brain tumours.

Further research needed to identify possible warning signs of a brain tumour. People with a brain tumour often visit their GP at least once before being diagnosed with a brain tumour, and more than half are diagnosed in emergency care.

Arshiya reports on an event she recently attended at Addenbrookes Hospital in Cambridge, held by Mr Mike Hart, a neurosurgery registrar.

As part of our commitment to increasing survival and halving the harm of brain tumours, we have committed over £1 million to transformative research

Our scientists in Heidelberg and London have discovered what drives the unpredictable growth of low grade brain tumours

SNO is an annual conference where those at the forefront of research to defeat brain tumours come together to share their work, discuss the progress that has been made and consider strategies for future development

We recently represented the charity at an international scientific conference called SNO in New Orleans

Hundreds more brain tumour patients are set to be offered access to experimental treatments over the next five years thanks to the Tessa Jowell BRAIN-MATRIX

Researchers have discovered a new drug could potentially halt the spread of glioblastoma cells

Scientists identify a subgroup of children diagnosed with medulloblastoma that could be given less aggressive treatments

Our Research Communications Assistant, Arshiya, gives an overview of the International Symposium on Paediatric Neuro-Oncology (ISPNO)

Results of two phase 2 clinical trials testing cabozantinib suggest that anti-angiogenic therapy could be used to treat glioblastomas

Our Research Engagement Manager Becky Birch, outlines developments highlighted by Tessa Jowell’s debate

Our Head of Research, Phil Hexley, outlines what happened at SNO: the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology

Our Head of Research, Phil Hexley, outlines what happened at SNO: the 22nd Annual Meeting and Education Day of the Society for Neuro-Oncology

PAC-1, an anti-cancer drug is approved for phase 1(b) clinical trials in humans by the US Food and Drug Administration

A gene therapy to treat recurrent high-grade gliomas is accelerated to Phase 3 clinical trials, after the success of Phase 1 clinical trials by the US Food and Drug Administration (FDA)

A research team at the University of Texas, led by Professor George Biros have been able to accurately characterise gliomas using a super computer

Professor Frank Winkler and his team at Heidelberg University in Germany have discovered a potential mechanism that could explain glioma recurrence